Estimation of SARS-CoV-2 Neutralizing Activity and Protective Immunity in Different Vaccine Types Using Three Surrogate Virus Neutralization Test Assays and Two Semiquantitative Binding Assays Targeting the Receptor-Binding Domain
Beomki Lee, Jae‐Hoon Ko, Kyoung Hwa Lee, Yong Chan Kim, Young Goo Song, Yoon Soo Park, Yae Jee Baek, Jin Young Ahn, Jun Yong Choi, Kyoung‐Ho Song, Eu Suk Kim, Seongman Bae, Sung‐Han Kim, Hye Won Jeong, Shin‐Woo Kim, Ki Tae Kwon, Su‐Hwan Kim, Hyeonji Jeong, Byoungguk Kim, Sung Soon Kim, Won Suk Choi, Kyong Ran Peck, Eun‐Suk Kang
Abstract
The coronavirus disease 2019 (COVID-19) pandemic continues to last, despite high COVID-19 vaccination rates. As many people experience breakthrough infection after prior infection and/or vaccination, estimating the neutralization activity and predicting the protective effect are major issues of concern. However, since standard neutralization tests are not available in most clinical laboratories, it would be beneficial if commercial assays could predict these aspects. In this study, we evaluated the performance of three sVNT assays and two semiquantitative binding assays targeting the receptor-binding domain with respect to the PRNT. Our results suggest that these assays could be used for predicting the protective effect by adjusting the cutoffs.